Cell Genesys, Inc. (CEGE) Closes Higher After Tests Show Vaccine Boosts Immune Response, Life Span of Cancer Patients
Shares of biotechnology company Cell Genesys (CEGE) jumped 20% Friday after the company reported clinical tests showed prostate cancer patients not only had an immune response to one of the company’s vaccines, GVAX, but they also lived twice as long as those who did not have an immune response. GVAX is designed to fight cancer by boosting the immune system response, and it did just that in 34 of 80 patients in the trial. Those 34 patients lived an average of 43 months, compared to the average of 21 months that patients without the response lived. Apparent associations between the…